0.6 0.008 (1.27%) | 02-11 16:17 | |||||||||||||
|
|
Short term | ![]() |
|||
Mid term | ![]() ![]() ![]() |
|||
Targets | 6-month : | 0.95 | 1-year : | 1.16 |
Resists | First : | 0.81 | Second : | 1 |
Pivot price | 0.67 ![]() |
|||
Supports | First : | 0.51 | Second : | 0.43 |
MAs | MA(5) : | 0.6 ![]() |
MA(20) : | 0.67 ![]() |
MA(100) : | 0.53 ![]() |
MA(250) : | 0.75 ![]() |
|
MACD | MACD : | 0 ![]() |
Signal : | 0 ![]() |
%K %D | K(14,3) : | 12.5 ![]() |
D(3) : | 14.2 ![]() |
RSI | RSI(14): 46.7 ![]() |
|||
52-week | High : | 3.09 | Low : | 0.4 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ AIMD ] has closed above bottom band by 25.3%. Bollinger Bands are 74.4% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 25 days. This is a sign that the current trend might continue.
If tomorrow: | Open lower | Open higher |
High: | 0.62 - 0.62 | 0.62 - 0.63 |
Low: | 0.58 - 0.59 | 0.59 - 0.59 |
Close: | 0.59 - 0.6 | 0.6 - 0.61 |
Ainos, Inc., a healthcare company, engages in the developing medical technologies for point-of-care testing and safe and novel medical treatment for disease indications. The company offers COVID-19 antigen rapid test kit and Ainos' cloud-based test management App, a cloud-based test management platform comprising an antigen rapid test kit, a personal application, and an enterprise app; COVID-19 nucleic acid test; volatile organic compounds point-of-care testing; Very Low-Dose Oral Interferon Alpha, a low-dose oral interferon alpha formulation based IFN-a's broad treatment applications; and Synthetic RNA developing a SRNA technology platform in Taiwan. The company was formerly known as Amarillo Biosciences, Inc. and changed its name to Ainos, Inc. in May 2021. Ainos, Inc. was incorporated in 1984 and is based in San Diego, California.
Mon, 27 Jan 2025
Ainos Secures Crucial Japanese Patent for Revolutionary Oral COVID Treatment VELDONA - StockTitan
Tue, 21 Jan 2025
Ainos AI Nose Technology Achieves 94% Accuracy in Health Diagnostics, Expands into Robotics - StockTitan
Fri, 17 Jan 2025
Ainos Receives 180-Day Nasdaq Extension to Meet $1 Minimum Bid Requirement - StockTitan
Fri, 19 Jul 2024
Ainos Inc. Faces Nasdaq Delisting Over Share Price Deficiency - Investing.com
Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
Exchange:
NASDAQ
|
|
Sector:
Healthcare
|
|
Industry:
Biotechnology
|
|
Shares Out | 0 (M) |
Shares Float | 14 (M) |
Held by Insiders | 8.38e+006 (%) |
Held by Institutions | 70.4 (%) |
Shares Short | 256 (K) |
Shares Short P.Month | 0 (K) |
EPS | -9.79e+006 |
EPS Est Next Qtrly | 0 |
EPS Est This Year | 0 |
EPS Est Next Year | 0 |
Book Value (p.s.) | 0 |
Profit Margin | 0 % |
Operating Margin | -35 % |
Return on Assets (ttm) | 985.4 % |
Return on Equity (ttm) | -28.1 % |
Qtrly Rev. Growth | 40630 % |
Gross Profit (p.s.) | 0 |
Sales Per Share | -50.08 |
EBITDA (p.s.) | -101667 |
Qtrly Earnings Growth | -2.8 % |
Operating Cash Flow | 0 (M) |
Levered Free Cash Flow | -6 (M) |
PE Ratio | -0.01 |
PEG Ratio | 0 |
Price to Book value | 0 |
Price to Sales | -0.02 |
Price to Cash Flow | 0.65 |
Dividend | 0 |
Forward Dividend | 634140 |
Dividend Yield | 0% |
Dividend Pay Date | Invalid DateTime. |
Ex-Dividend Date | Invalid DateTime. |